Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Dr. Agarwal's Health Care Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹443.00
High
₹451.20
Price Summary
| Previous Close | ₹443.20 |
|---|---|
| Day's Range | ₹443.00 - ₹451.20 |
| Open | ₹448.50 |
| 52 Week Range | ₹360.60 - ₹568.00 |
| Volume | 31,968 |
| Market Cap | ₹0.01 |
| Previous Close | ₹443.45 |
|---|---|
| Day's Range | ₹442.80 - ₹451.25 |
| Open | ₹448.45 |
| 52 Week Range | ₹360.55 - ₹567.80 |
| Volume | 2,215 |
| Market Cap | ₹0.01 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 141.68 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 106.97 |
| TTM EPS (₹) | 4.20 |
| P/E Ratio | 169.15 |
| Book Value(₹) | 7.03 |
| PAT Margin (%) | 6.45 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 14.32 |
| Trade Value ( ₹ in Lacs) | 9.82 |
|---|---|
| Market Cap (₹ in Mn) | 0.01 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 106.97 |
| TTM EPS (₹) | 4.20 |
| P/E Ratio | 169.15 |
| Book Value(₹) | 7.03 |
| PAT Margin (%) | 6.45 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 14.32 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 17110.0 | 4602.2 |
| Expenses | N/A | N/A |
| PBT | 1598.5 | 585.2 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1103.4 | 425.5 |
About Dr. Agarwal's Health Care Ltd.
| Founded | 2010 |
|---|---|
| NSE Symbol | AGARWALEYE |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,26,937.66 | 1,789.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,361.19 | 6,737.40 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,51,384.95 | 4,493.50 | 3,140.10 - 3,140.10 |
| Apollo Hospitals Enterprise Ltd. | 1,22,585.05 | 8,543.80 | 6,696.50 - 6,696.50 |
| Zydus Lifesciences Ltd. | 1,11,264.32 | 1,107.70 | 835.50 - 835.50 |
| Cipla Ltd. | 1,11,220.10 | 1,380.10 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,05,898.64 | 1,273.80 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,490.01 | 2,263.20 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 98,745.27 | 2,398.55 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 97,640.68 | 1,020.80 | 903.00 - 903.00 |
No Records Found
Latest News
May
15
2026
Posted on May 15th 2026
Dr. Agarwals Health Care informs about updates
Dr. Agarwals Health Care has informed that the Company is in receipt of a Show Cause Notice dated May 14, 2026 (SCN), from the Office of the Assistant Commissioner, GST & Central Excise, Nungambakkam, Chennai 600 034, alleging certain discrepancies in the returns / statements filed by the Company for the financial year 2022-23. The details as required in terms of regulation 30 read with Schedule III of the SEBI Listing regulations and the SEBI Master Circular concerning the aforesaid receipt of show cause notice, are enclosed as Annexure I. This information is also made available on the website of the Company at: https://dragarwals.co.in/dr-agarwals-health-care/#corporate-announcement.
The above information is a part of company’s filings submitted to BSE.
Read More
Jun
10
2026
Posted on Jun 10th 2026
Beryl Drugs informs about disclosure
Beryl Drugs has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi.
The above information is a part of company’s filings submitted to BSE.
Read More
Jun
10
2026
Posted on Jun 10th 2026
Concord Biotech informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Concord Biotech has informed that the Company has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA). According to market estimates, the U.S. market for Tofacitinib Tablets both strengths put together is approximately US$ 500 million. The approval positions the Company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets. The requisite details of terms of the provisions of Regulation 30 read with Schedule III and SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 are enclosed.
The above information is a part of company’s filings submitted to BSE.
Read More
Jun
10
2026
Posted on Jun 10th 2026
Lenskart Solutions informs about acquisition updates
Lenskart Solutions has informed that the company has acquired an additional 3% stake in Quantduo Technologies (Quantduo or GeoIQ)). Further, the Company had earlier acquired an additional 4.65% stake in Quantduo on March 16, 2026. Accordingly, the aggregate increase in the Company's shareholding in Quantduo since the last disclosure made by the Company is 7.65%. Consequent to the aforesaid acquisitions, the aggregate shareholding of the Company in Quantduo has increased from 92.35% to 100% of the fully diluted share capital of Quantduo and consequently, Quantduo has become a wholly-owned subsidiary of the Company. The details required under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) read with SEBI Master Circular bearing reference no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure – 1. The aforesaid details will also be hosted on the Company's website viz. https://www.lenskart.com/corporate/investorrelations.
The above information is a part of company’s filings submitted to BSE.
Read More
Jun
10
2026
Posted on Jun 10th 2026
Nureca informs about disclosure
Nureca has informed it enclosed disclosure received from Nectar Biopharma, Member of Promoter Group pursuant to Regulation 7(2) of PIT Regulations in respect of disposal of shares of the company through an off-market transaction. The disclosure is not required vide SEBI Circular No. SEBI/HO/ISD/ISD/CIR/P/2020/168 and SEBI/HO/ISD/ISD/CIR/P/2021/617 dated September 09, 2020 and August 13, 2021 respectively.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dr. Agarwal's Health Care Ltd. is ₹443.20 as of 2026-06-10.
The market capitalisation of Dr. Agarwal's Health Care Ltd. is ₹14,246.80 as of 2026-06-09.
The 1-year return of Dr. Agarwal's Health Care Ltd. is -5.30% as of 2026-06-10.
The P/E ratio of Dr. Agarwal's Health Care Ltd. is 169.15 as of 2026-06-10.
The 52-week high and low of Dr. Agarwal's Health Care Ltd. are ₹568.00 and ₹360.60, respectively, as of 2026-06-10.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
